Bayer Ag Na Stock Current Ratio

BAYN Stock  EUR 19.79  0.19  0.97%   
Bayer AG NA fundamentals help investors to digest information that contributes to Bayer AG's financial success or failures. It also enables traders to predict the movement of Bayer Stock. The fundamental analysis module provides a way to measure Bayer AG's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bayer AG stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Bayer AG NA Company Current Ratio Analysis

Bayer AG's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

 = 

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current Bayer AG Current Ratio

    
  1.18 X  
Most of Bayer AG's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bayer AG NA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition

In accordance with the recently published financial statements, Bayer AG NA has a Current Ratio of 1.18 times. This is 59.45% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The current ratio for all Germany stocks is 45.37% higher than that of the company.

Bayer Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bayer AG's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bayer AG could also be used in its relative valuation, which is a method of valuing Bayer AG by comparing valuation metrics of similar companies.
Bayer AG is currently under evaluation in current ratio category among its peers.

Bayer Fundamentals

About Bayer AG Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bayer AG NA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bayer AG using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bayer AG NA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Bayer Stock

Bayer AG financial ratios help investors to determine whether Bayer Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bayer with respect to the benefits of owning Bayer AG security.